BERG, biopharmaceutical company, that combines biology and technology to elucidate underlying mechanisms of disease, today announced the presentation of 4 posters at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, being held from March 29th – April 3rd. The poster on BERG’s leading product candidate, BPM 31510, emphasizes the potential mechanism of action in preclinical in vitro and in vivo models of Glioblastoma. Separate posters include data on predictive and prognostic biomarkers in pancreatic and prostate cancer.
“BERGs Interrogative Biology® platform is data agnostic, thus can be applied strategically to different therapeutic areas,” said Niven R. Narain, Ph.D., BERG co-founder, President and Chief Executive Officer. “The research presented this week at AACR further supports BERGs Phase I clinical trial in Glioblastoma. Other posters highlight the strength of BERG’s multi- omics capabilities to discovery biomarkers in specific prostate and pancreatic cancer cases. BERG is grateful for the collaborative opportunities that confirms it’s commitment to patients.”
The research was guided by BERG’s proprietary Interrogative Biology® platform, its hypothesis free, algorithm-based approach guides the discovery, development and clinical evaluation of product candidates to create the next generation of drugs and diagnostics.
Details of the abstracts and data presentations include:
1. Tuesday: April 2, 2019
8:00 am -12:00pm (Poster 3608): BPM31510 Exploits Differential Redox Vulnerabilities between Normal and Glioblastoma Cells to Mediate its Anti-Cancer Effect- in collaboration with Department of Neurology, Neurological Sciences and Adult Neuro-Oncology, Stanford Medicine, Palo Alto, CA
8:00 am – 12:00 pm (Poster 2772): Recurrent Alterations of the TNC in Highly Aggressive Neuroendocrine Sub-type of Prostate Cancer- in collaboration with Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, MD; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD.
2. Wednesday: April 3, 2019
8:00 am – 12:00 pm (Poster 4900): Dynamic Metabolic Response of Prostate Cancer Patients Treated with ADT and Low Carb Diet – in collaboration with Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai, Los Angeles, CA USA
3. Wednesday: April 3, 2019
8:00 am – 12:00 pm (Poster 4945): Project Survival: Engineering a Phenomic and Artificial Intelligence Driven Precision Medicine Biomarker Pipeline for Pancreatic Adenocarcinomas – in collaboration with Beth Israel Deaconess Medical Center, Boston, MA, Banner MD Anderson Cancer Center, Gilbert, AZ, Cancer Research and Biostatistics, Seattle, WA
Full abstracts of the posters are available on the AACR website (www.aacr.org).
BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimed at the most promising therapeutic targets and pathways. BERG has leveraged both Interrogative Biology and traditional R&D methods to develop a robust pipeline of first-in-class product candidates and diagnostics that advance bold innovations that have the potential to improve patient lives. To learn more about how we’re enabling bold innovation, visit berghealth.com.